Amneal Pharmaceuticals, Inc.
AMRX
$12.60
-$0.18-1.41%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -11.27% | 3.80% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -11.27% | 3.80% | |||
| Cost of Revenue | -22.10% | 5.78% | |||
| Gross Profit | 7.71% | 0.50% | |||
| SG&A Expenses | -5.20% | 6.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -6,300.00% | 99.15% | |||
| Total Operating Expenses | -16.96% | 1.24% | |||
| Operating Income | 23.48% | 22.76% | |||
| Income Before Tax | 45.15% | 1,157.53% | |||
| Income Tax Expenses | -61.57% | 124.24% | |||
| Earnings from Continuing Operations | 57.34% | 173.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -8.60% | 8.03% | |||
| Net Income | 77.49% | 1,380.62% | |||
| EBIT | 23.48% | 22.76% | |||
| EBITDA | 12.74% | 11.12% | |||
| EPS Basic | 76.68% | 1,386.67% | |||
| Normalized Basic EPS | 67.49% | 44.73% | |||
| EPS Diluted | 73.83% | 1,357.33% | |||
| Normalized Diluted EPS | 68.04% | 43.14% | |||
| Average Basic Shares Outstanding | 0.50% | 0.09% | |||
| Average Diluted Shares Outstanding | 0.26% | 1.03% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||